Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4958498 | 1.00 | CYP1A2 (0.47) | CYP1A2POLBMEN1ALDH1A1LMNA | |
| SCHEMBL4960465 | 0.70 | MAPKAPK2 (0.44) | CYP1A2POLB | |
| SCHEMBL14452553 | 0.68 | KMT2A (0.47) | CYP1A2POLBMEN1LMNAKMT2A | |
| SCHEMBL12737480 | 0.65 | IDH1 (0.44) | CYP1A2POLBLMNA | |
| SCHEMBL4876531 | 0.59 | CYP1A2 (0.44) | CYP1A2POLB | |
| SCHEMBL13815446 | 0.55 | CYP1A2 (0.36) | CYP1A2POLBMEN1ALDH1A1LMNA | |
| SCHEMBL3444514 | 0.54 | — | — | |
| SCHEMBL12133544 | 0.54 | — | — | |
| SCHEMBL4716796 | 0.54 | — | — | |
| SCHEMBL4330718 | 0.54 | CNR1 (0.36) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100569773-C | Novel azaindole thiazolinone as carcinostatic agent | HOFFMANN LA ROCHE (CH) | 2009-12-16 | — | — | CN | disclosed |
| EP-1805175-B1 | NOVEL AZAINDOLE THIAZOLINONES AS ANTI-CANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2008-03-05 | — | — | EP | disclosed |
| CN-101039943-A | Novel azaindole thiazolinones as anti-cancer agents | HOFFMANN LA ROCHE (CH) | 2007-09-19 | — | — | CN | disclosed |
| US-7247727-B2 | Azaindole thiazolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1805175-A1 | NOVEL AZAINDOLE THIAZOLINONES AS ANTI-CANCER AGENTS | F. Hoffmann-Roche AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| US-20060084674-A1 | Azaindole thiazolinones | CHEN SHAOQING | 2006-04-20 | — | — | US | disclosed |
| WO-2006040049-A1 | NOVEL AZAINDOLE THIAZOLINONES AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084674-A1 | Azaindole thiazolinones | CDK1, CDK2, CDK12 | CYP1A2 3707/4885POLB 1055/4885MEN1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.